



Recent Research on Neutralizing Antibody Response and SARS-CoV-2 Variants

Guest Editor:

Dr. Chloé Dimeglio

Virology Laboratory, Toulouse
University Hospital, 330 Avenue
de Grande Bretagne 31059, 31300
Toulouse, France

Deadline for manuscript
submissions:

6 April 2025

Message from the Guest Editor

Dear Colleagues,

COVID-19 continues to spread globally. Despite vaccination boosting, the risk of getting infected or reinfected with SARS-CoV-2 remains due to the emergence of viral variants. Often, these variants may evade naturally acquired or vaccine-induced immunity. Therefore, it is essential to study the relationship between genetic diversity, antibody response, and the evolution of SARS-CoV-2. The aim of this Special Issue is to evaluate recent research on the neutralizing antibody response to SARS-CoV-2 variants. We welcome original research articles and reviews. Research areas may include but are not limited to SARS-CoV-2 and vaccines, SARS-CoV-2 and natural infection, immunity mechanisms, competition between variants, vaccine escape, and SARS-CoV-2 dynamics.

We look forward to receiving your contributions.

Dr. Chloé Dimeglio

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com